Skip to Main Content

Bristol Myers Squibb said that it will purchase MyoKardia, an 8-year-old developer of an experimental heart drug, for $13.1 billion in cash.

The deal price, at $225 per MyoKardia share, represents a 61% premium to the closing price of MyoKardia shares on Friday.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED